Posted innews Oncology Otorhinolaryngology
Pathologic Response to Neoadjuvant Nivolumab Predicts Improved Survival in HPV‑Negative Head and Neck Cancer
A pooled analysis of two neoadjuvant nivolumab trials found that pathologic treatment effect >57% is associated with markedly improved 3‑year disease‑free and overall survival in HPV‑negative resectable HNSCC, suggesting pTE may be a useful early surrogate biomarker.